AML1/RUNX1 point mutation possibly promotes leukemic transformation in myeloproliferative neoplasms.
about
Genomic diversity in myeloproliferative neoplasms: focus on myelofibrosisChromosomal minimal critical regions in therapy-related leukemia appear different from those of de novo leukemia by high-resolution aCGH.Abrogation of RUNX1 gene expression in de novo myelodysplastic syndrome with t(4;21)(q21;q22).Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias.AML1 is overexpressed in patients with myeloproliferative neoplasms and mediates JAK2V617F-independent overexpression of NF-E2Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasmsClonal evolution revealed by whole genome sequencing in a case of primary myelofibrosis transformed to secondary acute myeloid leukemiaGenetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome.RUNX1 and RUNX1-ETO: roles in hematopoiesis and leukemogenesis.Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: does anything work?Molecular biology of Philadelphia-negative myeloproliferative neoplasmsAcute myeloid leukemia following a myeloproliferative neoplasm: clinical characteristics, genetic features and effects of therapy.A role for RUNX1 in hematopoiesis and myeloid leukemia.Inherited predisposition to myeloproliferative neoplasmsGenetic events other than BCR-ABL1.Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies.Relationship between RUNX1 and AXIN1 in ER-negative versus ER-positive Breast Cancer.Prognosis of Primary Myelofibrosis in the Genomic EraAberrant expression of RasGRP1 cooperates with gain-of-function NOTCH1 mutations in T-cell leukemogenesis.Mixed-phenotype acute leukemia (MPAL) exhibits frequent mutations in DNMT3A and activated signaling genes.Competing cell clones in myeloproliferative neoplasm.MicroRNA-125b-1 accelerates a C-terminal mutant of C/EBPα (C/EBPα-C(m))-induced myeloid leukemia.Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status.RUNX1 and CBFβ Mutations and Activities of Their Wild-Type Alleles in AML.Molecular mechanisms that produce secondary MDS/AML by RUNX1/AML1 point mutations.RUNX1 mutations are rare in chronic phase polycythaemia vera.
P2860
Q26770330-FAD7A304-CE1E-48DA-AFA5-5B797375622FQ33394269-F7F3BE9F-F9D0-4F5B-83E7-800D04D19A29Q33398370-413B72F1-DCBE-4EA9-96D8-4E201D4C02E5Q33647411-5AB82A7A-E9E7-400F-AD4C-0229AA6BD97DQ34022432-366B9EB7-F0EE-4008-A74A-8B4A7987BAE2Q35023473-ED8031DA-8A2A-4DC1-9E0B-85A71967C18DQ35217865-6981CBE8-9B21-470C-8753-5359FDF6888EQ35995222-A503D617-7BCD-4F09-864C-D767EF396CE6Q36206674-666620E1-3514-43BD-8EC3-8B4A949B99A6Q37968531-D816F32E-0D10-4887-9CCF-3548110C6905Q38050756-E87B8B50-3350-4C81-A222-E49734FD6CFFQ38097735-0AFC1CD5-ABBF-4131-AD6F-5570DDC15CD1Q38101285-6FE84F67-C3EA-42E0-BC5D-632DA6336D30Q38127417-DCC872F2-838A-44CB-8ECE-51E084B150D4Q38177162-483FF42F-B1A8-4A0C-8D49-2AE8079DE3D6Q38329285-E72BAC8B-6E85-4583-A129-28E8A031518DQ38722836-F1791288-4915-42C5-8204-17F8A34C7692Q38926804-452629C1-B18A-4185-AAE8-57EBC860DF9BQ39437389-57DD48A5-90A4-4E38-93D9-232B1360E67CQ42212772-FFEF96C2-5C2A-44F0-9169-9CE29BD27C59Q42575348-902A4F2D-EBE5-4D0C-B5CA-D364F0B88396Q44210348-34CFC724-72E3-49B8-8865-A91C622BFD50Q49472515-02A80F70-BCAD-4D71-AA46-F160D06B92A7Q51097615-C245936E-DFA4-43F8-B9E5-C3341711220EQ53272408-69D93BF5-AD67-4342-9A43-E19EB8651A26Q54611912-BA76BC12-2156-4223-9F05-A061711A6CF7
P2860
AML1/RUNX1 point mutation possibly promotes leukemic transformation in myeloproliferative neoplasms.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
AML1/RUNX1 point mutation poss ...... myeloproliferative neoplasms.
@en
AML1/RUNX1 point mutation poss ...... myeloproliferative neoplasms.
@nl
type
label
AML1/RUNX1 point mutation poss ...... myeloproliferative neoplasms.
@en
AML1/RUNX1 point mutation poss ...... myeloproliferative neoplasms.
@nl
prefLabel
AML1/RUNX1 point mutation poss ...... myeloproliferative neoplasms.
@en
AML1/RUNX1 point mutation poss ...... myeloproliferative neoplasms.
@nl
P2093
P1433
P1476
AML1/RUNX1 point mutation poss ...... myeloproliferative neoplasms.
@en
P2093
Akiro Kimura
Hironori Harada
Jun Imagawa
Yuka Harada
P304
P356
10.1182/BLOOD-2009-06-223982
P407
P577
2009-12-01T00:00:00Z